Abstract
Deprenyl, a monoamine oxidase (MAO) inhibitor with selective effects on MAO type-B at low doses, was administered to 13 patients with dementia of the Alzheimer type (DAT), a disorder reported to be associated with increased brain MAO-B activity. Cerebrospinal fluid was obtained for measurement of three monoamine metabolites, homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and 3-methoxy-4-hydroxyphenylglycol (MHPG), by high pressure liquid chromatography with electrochemical detection. Deprenyl treatment (10 mg/day) for 3–4 weeks was associated with small but statistically significant reductions in HVA (21%) and 5-HIAA (15%) compared to baseline values. Subsequent administration of deprenyl at the higher dose of 40 mg/day for 3–4 more weeks led to greater reductions in HVA (40%) and MHPG (43%) than 5-HIAA (20%). These dose-dependent reductions are consistent with in vitro biochemical and anatomical data from primate brain suggesting that at low doses of deprenyl, MAO-B inhibition might be expected to selectively affect dopamine and serotonin-containing neurons, while at higher doses (which lead to MAO-A as well as MAO-B inhibition), noradrenergic neurons may become relatively more affected by the drug.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adolfsson R, Gottfries CG, Roos BE, Winblad B (1979) Changes in the brain catecholamines in patients with dementia of the Alzheimer type. Br J Psychiatry 135:216–223
Adolfsson R, Gottfries CG, Oreland L, Wiberg A, Winblad B (1980) Increased activity of brain and platelet monoamine oxidase in dementia of the Alzheimer type. Life Sci 27:1029–1034
Alexopoulos GS, Lieberman KW, Young RC (1984) Platelet MAO activity in primary degenerative dementia. Am J Psychiatry 141:97–99
Baraczka K, Fekete MIK, Kanyicska B (1983) Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration. J Neural Transm 58:299–304
Birkmayer W, Riederer P, Youdim MBH (1982) (-)Deprenyl in the treatment of Parkinson's disease. Clin Neuropharmacol 5(2):195–230
Bowen DM, Spillane JA, Curzon G, Meier-Ruge W, White P, Goodhardt MJ, Iwangoff P, Davison AN (1979) Accelerated aging or selective neuronal loss as an important cause of dementia. Lancet 1:11–14
Burns RS, LeWitt P, Ebert MH, Parkenberg H, Kopin IJ (1985) The clinical syndrome of striatal dopamine deficiency: Parkinsonism induced by 1-methyl-4-phenyl-1,2,2,6-tetrahydrop (MPTP). N Engl J Med 312:1418–1421
Crow TJ, Cross AJ, Cooper JJ, Deakin JFW, Ferrier IN, Johnson JA, Joseph MH, Owen F, Poulter M, Lofthouse R, Corsellis JAN, Chambers DR, Blessed G, Perry EK, Perry RH, Tomlinson BE (1984) Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides. Neuropharmacology 23:1561–1569
Eisler T, Terawainen H, Nelson R, Krebs H, Weise V, Lake CR, Ebert MH, Whetzel N, Murphy DL, Kopin IJ, Calne DB (1981) Deprenyl in Parkinson disease. Neurology 31:19–23
Garrick N, Murphy DL (1980) Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain. Psychopharmacology 72:27–33
Glover V, Sandler M, Owen F, Riley GJ (1977) Dopamine is a monoamine B substrate in man. Nature 265:80–81
Gottfries CG, Kjallquist A, Ponten U, Roos BE, Sundbarg G (1974) Cerebrospinal fluid pH and monoamine and glucolytic metabolites in Alzheimer's disease. Br J Psychiatry 124:280–287
Gottfries CG (1985) Alzheimer's disease and senile dementia: biochemical characteristics and aspects of treatment. Psychopharmacology 86:245–252
Hachinski VC, Iliff LD, Phil M, Zilhka E, DuBoular GH, McAllister VA, Marshall J, Russell RWR, Symon L (1975) Cerebral blood flow in dementia. Arch Neurol 32:632–637
Heikkila RE, Hess A, Davoisin RC (1985) VI. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse: Relationships between monoamine oxidase, MPTP metabolism and neurotoxicity. Life Sci 46:231–236
Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140:566–572
Kopin IJ, Gordon EK, Jimerson DC, Polinsky RJ (1983) Relation between plasma and cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylglycol. Science 219:73–75
Linnoila M, Guthrie S, Lane EA, Karoum F, Rudorfer M, Potter WZ (1986) Clinical studies on norepinephrine metabolism: How to interpret the numbers. Psychiatry Res 17:229–239
Major LF, Murphy DL, Lipper S, Gordon E (1979) Effects of clorgyline and pargyline on deaminated metabolites of norepinepherine, dopamine and serotonin in human cerebrospinal fluid. J Neurochem 32:229–231
Mann JJ, Gershon S (1980) l-Deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression. Life Sci 26:977
Mendelewicz J, Youdim MBH (1983) l-Deprenyl, a selective monoamine oxidase type B inhibitor, in the treatment of depression: A double-blind evaluation. Br J Psychiatry 142:508–511
Mendis N, Pare CMB, Sandler M, Glover V, Stern GM (1981) Is the failure of (-) deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect. Psychopharmacology 73:87–90
Parkes JD, Marsden CD, Rees JE, Curzon G, Kantamaneni BD, Knill-Jones R, Akbar A, Das S, Kataria M (1974) Parkinson's disease, cerebral arteriosclerosis and senile dementia. Q J Med 169:49–61
Raskind MA, Peskind ER, Halter JB, Jimerson DC (1984) Norepinepherine and MHPG levels in CSF and plasma of Alzheimer's disease. Arch Gen Psychiatry 41:343–346
Riederer P, Fellinger K, Seeman D (1984) Monoamine oxidase and Parkinsonism. In: Tipton KF, Dostert P, Benedetti MS (eds) Monoamine oxidase and disease: prospects for therapy with reversible inhibitors. Academic Press London
Robinson DS, Davis JM, Nies A, Ravaris CL, Sylwester D (1971) Relation of sex and aging to monoamine oxidase activity in human brain, plasma and platelets. Arch Gen Psychiatry 24:536–539
Scheinin M, Chank W, Kirk KL, Linnoila M (1983) Simultaneous determination of 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, and homovanillic acid in cerebrospinal fluid with high-performance liquid chromatography using electrochemical detection. Anal Biochem 131:246–253
Soininen H, MacDonald E, Rekonen M, Riekkinen PJ (1981) Homovanillic acid and 5-hydroxyindoleacetic acid levels in cerebrospinal fluid of patients with senile dementia of the Alzheimer type. Acta Neurol Scand 64:101–107
Stern GM, Lees AJ, Sandler M (1978) Recent observations on the clinical phrmacology of (-)deprenyl. J Neural Transm 43:245–251
Sunderland T, Mueller EA, Cohen RM, Jimerson DC, Pickar D, Murphy DL (1985) Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology 36:432–437
Varga E, Tringer L (1967) Clinical trial of a new type promptly acting psychoenergetic agent (phenyl-isopropyl-methylpropinyl-HCL, E-250). Acta Med Acad Sci Hung Tomus 23:289–295
Volicer L, Direnfield LK, Freedman M, Albert ML, Langlais PJ, Bird EA (1985) Serotonin and 5-hydroxyindoleacetic acid in CSF: difference in Parkinson's disease and dementia of the Alzheimer's type. Arch Neurol 42:127–129
Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW (1985) Distinct monoamine oxidase A and B populations in primate brain. Science 230:181–183
Wood PL, Etienne P, Lal S, Gauthier S, Cajal S, Nair NPV (1982) Reduced lumbar CSF somatostatin levels in Alzheimer's disease. Life Sci 31:2073–2079
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sunderland, T., Tariot, P.N., Cohen, R.M. et al. Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease. Psychopharmacology 91, 293–296 (1987). https://doi.org/10.1007/BF00518180
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00518180